Bridgefront Capital, LLC Gilead Sciences, Inc. Transaction History

Bridgefront Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $674,569 - $822,620	9,424 New	9,424 $690,000
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $447,698 - $510,663	5,890 New	5,890 $453,000
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $205,714 - $231,695	3,564 New	3,564 $220,000
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $273,399 - $294,968	-4,039 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$63.47 - $69.35 $256,355 - $280,104	4,039 New	4,039 $278,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.